StockData
Galectin Therapeutics Inc logo

Galectin Therapeutics Inc (GALT) stock

GALTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 0/30
$2.91−0.11 (-3.64%)

Close on Nov 17, 2026Market cap $293.47MP/E –Yield –

Galectin Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Galectin Therapeutics's enterprise value was $204.90M on Nov 11, 2026, against $357.90M a year earlier. Over the last 5 years it ranged from $45.01M to $358.42M, with a median of $103.58M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$204.90M-20.2%
2025Dec 31, 2025$256.68M+381.4%
2024Dec 31, 2024$53.32M-35.2%
2023Dec 29, 2023$82.31M+60.4%
2022Dec 30, 2022$51.32M-40.5%
2021Dec 31, 2021$86.24M-9.5%
2020Dec 31, 2020$95.30M-14.7%
2019Dec 31, 2019$111.71M-14.7%
2018Dec 31, 2018$130.96M+16.9%
2017Dec 29, 2017$112.08M+779.4%
2016Dec 30, 2016$12.74M-28.9%
2015Dec 31, 2015$17.92M-60.7%
2014Dec 31, 2014$45.57M-65.7%
2013Dec 31, 2013$132.90M+513.3%
2012Dec 31, 2012$21.67M-67.1%
2011Dec 30, 2011$65.89M–

More Galectin Therapeutics figures

See a number that looks wrong?